Verdict: Side-by-side breakdown using the Bull Rankings model. ETON scored 66.7, KNSA scored 67.1 — KNSA leads.
Compare another set
Different reporting periods. ETON's fundamentals are as of June 2026, but KNSA's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
ETON
Eton Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
66.7
$55.21 · $1.6B
fundamentals as of
Score gap
0.4
KNSA leads
KNSA
Kiniksa Pharmaceuticals International, plc
Drug Manufacturers - Specialty & Generic · Quality-Growth
67.1
$79.78 · $6.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthETON+104.9%
Strongest balance sheetKNSA0.01
Highest qualityKNSA64 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ETON
stronger →← stronger
KNSA
58
Qualityreturns · margins · balance sheet
64
98
Growthrevenue & earnings expansion
99
52
Valuevaluation vs sector peers
48
KNSA is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ETON
KNSA
-$268kF
FCF
$164mC
+104.9%A
Rev
+56.7%A
0.63C+
D/E
0.01A-
14.9xC
P/S
—
1.64C+
PEG
2.03C
—
P/E
79.8xD
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ETON
KNSA
—
Price vs fair valuelower is cheaper
63% above
—
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~28%/yr
—
1-yr DCF upside
-53%
—
5-yr DCF upside
-39%
—
10-yr DCF upside
-10%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Drug Manufacturers - Specialty & Generic · market cap $1.6b. 17% off the 52-week high of $66.37. Revenue growing +105% — in hypergrowth territory. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $71.00 (implying +29% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$268k) — capital raises or debt issuance likely required; dilution / leverage risk. Trailing P/E 138.0x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. P/S 14.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Drug Manufacturers - Specialty & Generic · market cap $6.2b. 4% off the 52-week high of $82.94. Revenue growing +57% — in hypergrowth territory. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $98.00 (implying +23% upside).
Moat
ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 79.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ETON and KNSA diverge
The two are effectively level on the headline score. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
QualityETON 58.2 · KNSA 64.0KNSA +5.8
ValueETON 52.1 · KNSA 47.8ETON +4.3
GrowthETON 98.0 · KNSA 99.0level
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is KNSA or ETON the better stock?
KNSA scores higher: KNSA 67.1, ETON 66.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do KNSA and ETON differ most?
The widest gap is quality, where KNSA leads by 6 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are KNSA and ETON scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.